•  
  •  
  •  
  •  

2026-04-17 23:35:23

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Hathway Cable and Datacom Limited Announces Audited Financial Results for FY 2025-26
  • Jio Financial Services Limited Reports Strong Revenue Growth for FY 2025-26
  • Mastek Limited Reports Robust Revenue Growth and Enhanced Profitability for FY 2025-26
  • Bajaj Consumer Care Limited Reports 52% Surge in Annual Net Profit for FY 2025-26
  • National Standard (India) Limited Announces FY 2025-26 Financial Results

Keywords Selected:  IOC

Research

  • Biocon Limited - Generics & research grow; biosimilar stagnates - ICICI Securities
  • Q4FY22 Result Update – Biocon Ltd - ICICI Direct
  • Biocon - Q4FY22 First Cut - ICICI Direct
  • Q3FY22 Result Update - Biocon Ltd - ICICI Direct
  • Q2FY22 Result Update - Biocon Ltd - ICICI Direct

Stock Report

  • Biocon Pharma Ltd receives U.S. FDA Approval for Dapagliflozin Tablets, 5 mg and 10 mg
  • Indian Oil Corporation Ltd - Operational Performance Highlights of 2025-26
  • Shreehas Tambe Appointed CEO & Managing Director of Biocon Limited, Effective April 1, 2026
  • Indian Oil Corporation Limited declares 2nd interim dividend of Rs. 2
  • BMW Industries enters into an agreement with Indian Oil Corporation Ltd for supply of Piped Natural Gas
  • Biocon obtains approval for weight management drug, Liraglutide, in the United States
  • Pine Labs awarded multi-year contracts by top 3 Indian OMCs for nationwide Digital Payments Platform Modernisation
  • EP Biocomposites Partners with IISc Bengaluru
  • Fitch Ratings Revises Biocon Biologics Outlook from 'Stable' to 'Positive'
  • East India Drums and Barrels Manufacturing Ltd receives LOA from IOCL
  • Biocon Ltd signs out-licensing agreement with Ajanta to market Semaglutide in 26 countries
  • Ajanta signs in-licensing agreement with Biocon for marketing Semaglutide in 26 countries
  • Biocon Biologics Secures Full Global Rights to Biosimilar Adalimumab through Expanded FKB In-Licensing Agreement
  • Biocon Ltd receives EIR from USFDA with VAI status for Cranbury facility
  • Biocon Biologics Recognized as Asia IP Elite for 2025 by IAM
  • Biocon Limited launches its Glucagon-like Peptide-1, Liraglutide, in the Netherlands
  • Biocon Biologics Signs Settlement and License Agreement to Commercialize Biosimilar Aflibercept Worldwide
  • Biocon Ltd to integrate Biocon Biologics Ltd to create a Unified Global Biopharmaceutical Leader
  • Biocon Biologics Secures Market Entry Date for Denosumab Biosimilars in Europe and Rest of the World
  • Biocon Biologics' Drug Substance Facility in Bengaluru Classified as Voluntary Action Indicated
  • Biocon Pharma Ltd receives approval from USFDA for its ANDA
  • Loyal Equipments Ltd receives order from Indian Oil Corporation Ltd
  • Krebs Biochemicals and Industries Ltd Q2 FY2026 loss at Rs. 6.14 crores
  • Indian Oil Corporation Ltd consolidated Q2 FY2025-26 net profit climbs to Rs. 7817.55 crores

Latest Post

  • Hathway Cable and Datacom Limited Announces Audited Financial Results for FY 2025-26
  • Jio Financial Services Limited Reports Strong Revenue Growth for FY 2025-26
  • Mastek Limited Reports Robust Revenue Growth and Enhanced Profitability for FY 2025-26
  • Bajaj Consumer Care Limited Reports 52% Surge in Annual Net Profit for FY 2025-26
  • National Standard (India) Limited Announces FY 2025-26 Financial Results


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025